健康元(600380.SH):4項藥品擬中標第五批國家組織藥品集採
格隆匯6月23日丨健康元(600380.SH)公吿,2021年6月23日,公司及控股子公司麗珠醫藥集團股份有限公司參加了聯合採購辦公室組織的第五批全國藥品集中採購。
公司及麗珠集團的相關藥品吸入用布地奈德混懸液、吸入用複方異丙託溴銨溶液、吸入用異丙託溴銨溶液、替硝唑片擬中選本次集中採購。上述產品首年的約定採購金額約為1.60億元,佔2020年度營業收入比例為1.19%。
本次藥品集中採購是國家組織的第五批國家藥品集中採購,在執行上要求全國醫療機構優先使用集中採購中選品種,並確保完成約定採購量。若確定中選,簽訂購銷合同並實施後,將有利於上述產品快速打開國內銷售市場,提高市場佔有率,促進公司製劑業務的進一步發展,提升公司的品牌影響力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.